Tandem Diabetes Care Inc (FRA:TD5A)
€ 46.5 -0.61 (-1.29%) Market Cap: 3.09 Bil Enterprise Value: 3.10 Bil PE Ratio: 0 PB Ratio: 13.74 GF Score: 78/100

Tandem Diabetes Care Inc at Raymond James Institutional Investors Conference Transcript

Mar 06, 2024 / 04:00PM GMT
Release Date Price: €24.74 (-6.64%)
Jayson Tyler Bedford
Raymond James & Associates, Inc., Research Division - MD & Senior Medical Supplies and Devices Analyst

Good morning. I think we'll get started here. I'm Jayson Bedford, I cover the medtech sector here at Raymond James. Thank you for enduring a few days here. Today the 45th Annual Raymond James Institutional Investors Conference.

We're very pleased to have with us the senior management team from Tandem Diabetes. We have the company's CEO, John Sheridan, the company's CFO, Leigh Vosseller. And we really appreciate the -- that the time they're giving us. I think we'll go through a quick presentation, and I'll have some questions.

John F. Sheridan
Tandem Diabetes Care, Inc. - President, CEO & Director

Well, welcome, everybody. Thanks, Jayson. I'm going to start off with just -- I am going to be having forward-making -- forward-looking statements. And so would you please go to our website and look at the Investor section in terms of how to deal with that.

Sorry about that. So Tandem has been around for -- about

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot